Publication

The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties

Huizinga, F., Heutink, J., Haan, de, G., Lijn, van der, I., Feen, van der, F., Vrijling, A., Melis-Dankers, B., Vries, de, S., Tucha, O. & Koerts, J., 10-Apr-2019, (Unpublished).

Research output: Contribution to conferencePosterAcademic

APA

Huizinga, F., Heutink, J., Haan, de, G., Lijn, van der, I., Feen, van der, F., Vrijling, A., ... Koerts, J. (2019). The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties. Poster session presented at Heymans Symposium 2019, .

Author

Huizinga, Famke ; Heutink, Joost ; Haan, de, Gera ; Lijn, van der, Iris ; Feen, van der, Fleur ; Vrijling, Anne ; Melis-Dankers, Bart ; Vries, de, Stefanie ; Tucha, Oliver ; Koerts, Janneke. / The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties. Poster session presented at Heymans Symposium 2019, .

Harvard

Huizinga, F, Heutink, J, Haan, de, G, Lijn, van der, I, Feen, van der, F, Vrijling, A, Melis-Dankers, B, Vries, de, S, Tucha, O & Koerts, J 2019, 'The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties' Heymans Symposium 2019, 10/04/2019 - 10/04/2019, .

Standard

The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties. / Huizinga, Famke; Heutink, Joost; Haan, de, Gera; Lijn, van der, Iris; Feen, van der, Fleur; Vrijling, Anne; Melis-Dankers, Bart; Vries, de, Stefanie; Tucha, Oliver; Koerts, Janneke.

2019. Poster session presented at Heymans Symposium 2019, .

Research output: Contribution to conferencePosterAcademic

Vancouver

Huizinga F, Heutink J, Haan, de G, Lijn, van der I, Feen, van der F, Vrijling A et al. The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties. 2019. Poster session presented at Heymans Symposium 2019, .


BibTeX

@conference{9b6bd550fb634f69a1f570405a366f2f,
title = "The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties",
abstract = "Objectives:A 21-item Screening of Visual Complaints (SVC) questionnaire was developed within an expert group for the assessment of visual complaints in patients with Parkinson’s disease (PD), multiple sclerosis (MS) or early dementia. The present study aims to evaluate the psychometric properties of the SVC in a large community-sample by examining its factor structure, internal consistency, convergent and divergent validity, and test-retest reliability.Materials:The SVC, Cerebral Visual Disorders questionnaire (CVS), National Eye Institute Visual Function Questionnaire–25 (NEI-VFQ-25), Behavior Rating Inventory of Executive Function-A (BRIEF-A), questionnaire for Experiences of Attention Deficits (FEDA), Depression Anxiety Stress Scale–21 (DASS-21) and the Structured Inventory for Malingered Symptomatology (SIMS) were completed online.Methods:In total 1,461 healthy Dutch participants (18-95 years) completed all questionnaires; 66 participants completed the SVC again after two weeks to evaluate test-retest reliability. The dataset was randomly split in two subsamples in order to conduct exploratory and confirmatory factor analyses. All other analyses were performed within the complete sample.Results:From the exploratory factor analysis a three-factor model of the SVC was extracted: reduced visual perception, altered visual perception and ocular discomfort. The confirmatory factor analysis showed this model to be valid. The SVC showed an acceptable convergent validity (NEI-VFQ-25: r=-0.71; CVS: r=0.84) and divergent validity (SIMS: r=0.26; BRIEF-A: r=0.29; FEDA: r=0.40; DASS-21: r=0.34). The internal consistency (Cronbach’s alpha = 0.85) and test-retest reliability (ICC=0.82) were sufficient. Discussion:The total score of the SVC can be used to screen for the degree of visual complaints and to define change over time in case of repeated assessments. Subscale scores can support a more detailed evaluation and might guide further assessment of visual functioning. The SVC needs, however, further validation in clinical groups of patients with PD, MS or early dementia. Conclusion:The SVC is a valid and reliable tool for the assessment of subjective visual complaints in a community-sample and appears promising for use in clinical practice of patients with PD, MS or early dementia.",
author = "Famke Huizinga and Joost Heutink and {Haan, de}, Gera and {Lijn, van der}, Iris and {Feen, van der}, Fleur and Anne Vrijling and Bart Melis-Dankers and {Vries, de}, Stefanie and Oliver Tucha and Janneke Koerts",
year = "2019",
month = "4",
day = "10",
language = "English",
note = "Heymans Symposium 2019 ; Conference date: 10-04-2019 Through 10-04-2019",

}

RIS

TY - CONF

T1 - The development of the Screening of Visual Complaints questionnaire for patients with neurodegenerative disorders: Evaluation of psychometric properties

AU - Huizinga, Famke

AU - Heutink, Joost

AU - Haan, de, Gera

AU - Lijn, van der, Iris

AU - Feen, van der, Fleur

AU - Vrijling, Anne

AU - Melis-Dankers, Bart

AU - Vries, de, Stefanie

AU - Tucha, Oliver

AU - Koerts, Janneke

PY - 2019/4/10

Y1 - 2019/4/10

N2 - Objectives:A 21-item Screening of Visual Complaints (SVC) questionnaire was developed within an expert group for the assessment of visual complaints in patients with Parkinson’s disease (PD), multiple sclerosis (MS) or early dementia. The present study aims to evaluate the psychometric properties of the SVC in a large community-sample by examining its factor structure, internal consistency, convergent and divergent validity, and test-retest reliability.Materials:The SVC, Cerebral Visual Disorders questionnaire (CVS), National Eye Institute Visual Function Questionnaire–25 (NEI-VFQ-25), Behavior Rating Inventory of Executive Function-A (BRIEF-A), questionnaire for Experiences of Attention Deficits (FEDA), Depression Anxiety Stress Scale–21 (DASS-21) and the Structured Inventory for Malingered Symptomatology (SIMS) were completed online.Methods:In total 1,461 healthy Dutch participants (18-95 years) completed all questionnaires; 66 participants completed the SVC again after two weeks to evaluate test-retest reliability. The dataset was randomly split in two subsamples in order to conduct exploratory and confirmatory factor analyses. All other analyses were performed within the complete sample.Results:From the exploratory factor analysis a three-factor model of the SVC was extracted: reduced visual perception, altered visual perception and ocular discomfort. The confirmatory factor analysis showed this model to be valid. The SVC showed an acceptable convergent validity (NEI-VFQ-25: r=-0.71; CVS: r=0.84) and divergent validity (SIMS: r=0.26; BRIEF-A: r=0.29; FEDA: r=0.40; DASS-21: r=0.34). The internal consistency (Cronbach’s alpha = 0.85) and test-retest reliability (ICC=0.82) were sufficient. Discussion:The total score of the SVC can be used to screen for the degree of visual complaints and to define change over time in case of repeated assessments. Subscale scores can support a more detailed evaluation and might guide further assessment of visual functioning. The SVC needs, however, further validation in clinical groups of patients with PD, MS or early dementia. Conclusion:The SVC is a valid and reliable tool for the assessment of subjective visual complaints in a community-sample and appears promising for use in clinical practice of patients with PD, MS or early dementia.

AB - Objectives:A 21-item Screening of Visual Complaints (SVC) questionnaire was developed within an expert group for the assessment of visual complaints in patients with Parkinson’s disease (PD), multiple sclerosis (MS) or early dementia. The present study aims to evaluate the psychometric properties of the SVC in a large community-sample by examining its factor structure, internal consistency, convergent and divergent validity, and test-retest reliability.Materials:The SVC, Cerebral Visual Disorders questionnaire (CVS), National Eye Institute Visual Function Questionnaire–25 (NEI-VFQ-25), Behavior Rating Inventory of Executive Function-A (BRIEF-A), questionnaire for Experiences of Attention Deficits (FEDA), Depression Anxiety Stress Scale–21 (DASS-21) and the Structured Inventory for Malingered Symptomatology (SIMS) were completed online.Methods:In total 1,461 healthy Dutch participants (18-95 years) completed all questionnaires; 66 participants completed the SVC again after two weeks to evaluate test-retest reliability. The dataset was randomly split in two subsamples in order to conduct exploratory and confirmatory factor analyses. All other analyses were performed within the complete sample.Results:From the exploratory factor analysis a three-factor model of the SVC was extracted: reduced visual perception, altered visual perception and ocular discomfort. The confirmatory factor analysis showed this model to be valid. The SVC showed an acceptable convergent validity (NEI-VFQ-25: r=-0.71; CVS: r=0.84) and divergent validity (SIMS: r=0.26; BRIEF-A: r=0.29; FEDA: r=0.40; DASS-21: r=0.34). The internal consistency (Cronbach’s alpha = 0.85) and test-retest reliability (ICC=0.82) were sufficient. Discussion:The total score of the SVC can be used to screen for the degree of visual complaints and to define change over time in case of repeated assessments. Subscale scores can support a more detailed evaluation and might guide further assessment of visual functioning. The SVC needs, however, further validation in clinical groups of patients with PD, MS or early dementia. Conclusion:The SVC is a valid and reliable tool for the assessment of subjective visual complaints in a community-sample and appears promising for use in clinical practice of patients with PD, MS or early dementia.

M3 - Poster

ER -

ID: 103419876